GAIN THERAPEUTICS, INC Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax
GAIN THERAPEUTICS, INC (GANX) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax of $1.02 thousand as of 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Notes › Debt and Equity Securities
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2023-05-12
- 2023-03-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $1.02K.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2023-03-31 | $1.02K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |